Research

Life Sciences & Biotechnology

Title :

Development of Novel Purine Nucleoside-Quinoline Conjugates as Effective Inhibitors for Chikungunya and Dengue Viruses

Area of research :

Life Sciences & Biotechnology

Focus area :

Medicinal Chemistry

Principal Investigator :

Dr. Rakesh Kumar, Dr. B R Ambedkar National Institute of Technology Jalandhar, Punjab

Timeline Start Year :

2024

Timeline End Year :

2027

Contact info :

Details

Executive Summary :

The re-emergence of vector-borne infections, such as Chikungunya and Dengue, poses a significant health and economic threat worldwide. India, being a densely populated country, is prone to infection outbreaks. The lack of an approved vaccine for these viruses makes the situation vulnerable. Quinoline, a privileged scaffold in medicinal chemistry, remains the preferred pharmacophore in antiviral drug design. Quinoline-derived antimalarial drug, chloroquine, has been reported to inhibit these viruses. Nucleoside analogs are another important class of broad-spectrum antivirals that have shown potency against these viruses. The conjugation of nucleoside scaffolds to bioactive molecules has shown to significantly improve their bioactivity. Novel quinoline-purine nucleoside conjugates (adenosine and deoxyadenosine) conjugates are proposed as effective CHIKV and DENV inhibitors. The study will use an environmentally friendly approach to access a library of novel adenosine and deoxyadenosine conjugates of quinoline N-oxides. Molecular docking studies will be performed with viral proteins to understand their interactions and assess structure activity relations for designing effective inhibitors. Antiviral activities will be assessed through cell-based antiviral assays using previously isolated strains.

Co-PI:

Prof. shailly Tomar, Indian Institute of Technology Roorkee, Uttarakhand,Roorkee (247667)

Total Budget (INR):

44,06,000

Organizations involved